FDA Raises Red Flags on Capricor’s Deramiocel Trial Data
Event summary
- On July 27, 2026, the FDA released briefing documents questioning Capricor’s analysis of the HOPE-3 trial for deramiocel.
- The FDA staff deemed the conversion of results 'not scientifically justified' and concluded an unfavorable benefit-risk assessment.
- On July 29, 2026, the FDA advisory committee voted 9–3 that evidence did not support deramiocel’s effectiveness in treating cardiomyopathy.
- Capricor’s stock price dropped approximately 65% on July 27 and further declined following the committee vote.
The big picture
Capricor Therapeutics faces a critical juncture as the FDA challenges the scientific validity of its deramiocel trial data, raising broader questions about the reliability of biotech clinical trials and investor due diligence. The sharp stock price decline underscores the market’s sensitivity to regulatory setbacks in the high-stakes biopharmaceutical sector.
What we're watching
- Regulatory Headwinds
- How the FDA’s skepticism will impact Capricor’s future clinical trials and regulatory approvals.
- Investor Confidence
- Whether Capricor can regain investor trust after significant stock price declines.
- Legal Exposure
- The pace at which securities litigation may escalate following the FDA’s findings.
Related topics